Home/Pipeline/COV19 qcLAMP Kit

COV19 qcLAMP Kit

SARS-CoV-2 Infection

ApprovedCommercial (CE-IVD)

Key Facts

Indication

SARS-CoV-2 Infection

Phase

Approved

Status

Commercial (CE-IVD)

Company

BIOPIX-T

About BIOPIX-T

Founded in 2019 as a spin-off from IMBB-FORTH, BIOPIX-T is building a diagnostics ecosystem centered on its proprietary, 3D-printed Pebble device, which performs real-time quantitative colorimetric LAMP (qcLAMP) assays. The company has achieved CE-IVD certification for its platform and associated test kits, targeting the infectious disease diagnostics market with a focus on accessibility and ease of use. Backed by venture capital and angel investors, BIOPIX-T is led by a team of scientists and professionals aiming to expand its product portfolio and global presence.

View full company profile

Therapeutic Areas

Infectious Disease Oncology

Other SARS-CoV-2 Infection Drugs

Drug	Company	Phase	Status
Talis One COVID-19 Test	Talis Biomedical	Commercial (EUA)	Terminated
Logix Smart COVID-19 Test	Co-Diagnostics	Commercial	Marketed
GenBody COVID-19 Ag Test	GenBody	Approved	Active
CovidDetect	Prime Discoveries	Commercial	Active
FabenCOV® (e-FabRIC)	Fabentech	Phase 2	Active
Favipiravir	Viriom	Bioequivalence	Active
EDP-323	Enanta Pharmaceuticals	Phase 1	Active
InteliSwab® COVID-19 Rapid Antigen Test	OraSure Technologies	Approved	Commercial